Menopur (Menotrophin)

Menotrophin provides exogenous follicle‑stimulating hormone (FSH) and luteinising hormone (LH) that bind to their respective receptors on ovarian granulosa and theca cells. This activation promotes follicle growth, estrogen synthesis, and final maturation of oocytes, enabling ovulation or retrieval of multiple eggs for IVF.

The dose of Menopur is individualized; the prescribing clinician determines the amount and duration based on the patient’s ovarian reserve, response to prior cycles, and the specific assisted reproduction protocol. Dosing may start at low units and be adjusted according to ultrasound and hormone monitoring.

Menopur is intended for use before conception to induce ovulation or stimulate the ovaries; its safety in established pregnancy has not been established, and it is generally not recommended during pregnancy. Limited data are available for breastfeeding, so the drug should be avoided unless the benefit outweighs potential risk.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with import documentation.

Menopur combines both FSH and LH activity in a single preparation, whereas some alternatives provide only recombinant FSH (e.g., Gonal‑F) or separate LH preparations. The combined formulation can simplify dosing and may be advantageous for patients with low endogenous LH, but individual response varies, and clinicians choose agents based on patient characteristics and protocol requirements.

Menopur must be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F). It should be kept in its original carton to protect from light, must not be frozen or shaken, and should be used before the expiration date. Once removed from refrigeration, the product should be administered promptly and any unused portion discarded.

Menopur is supplied as a sterile injection solution for subcutaneous administration. The prescribed dose is drawn into a syringe and injected into the subcutaneous tissue of the abdomen or thigh, typically once daily, following the schedule outlined by the fertility specialist. Proper aseptic technique and rotation of injection sites are recommended to minimize local reactions.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause abdominal distension, rapid weight gain, and, in severe cases, thromboembolic events or renal impairment. Multiple pregnancy is another concern, as is the rare possibility of severe allergic reactions. Patients should be monitored closely for these complications throughout treatment.

Menopur is contraindicated in individuals with known hypersensitivity to menotrophin or any component of the formulation, in those with active ovarian cysts, uncontrolled thyroid disease, or severe ovarian hyperstimulation syndrome. It should also be avoided in pregnant women and is not recommended for patients with uncontrolled endocrine disorders without specialist supervision.